Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 12,946 Shares

Key Points

• CFO Adam Scott Levy of Mineralys Therapeutics sold 12,946 shares of the company's stock on July 28th, valued at approximately $181,761.84, representing a 6.27% decrease in his holdings.
• The current stock price for MLYS is around $14.49, with a market cap of $944.46 million and a 52-week trading range between $8.24 and $18.38.
• Several institutional investors are increasing their stakes in Mineralys Therapeutics, with over 84% of the stock owned by institutional investors and hedge funds.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 12,946 shares of Mineralys Therapeutics stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $14.04, for a total value of $181,761.84. Following the sale, the chief financial officer directly owned 193,666 shares in the company, valued at $2,719,070.64. The trade was a 6.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Adam Scott Levy also recently made the following trade(s):

• On Wednesday, July 30th, Adam Scott Levy sold 59,925 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $14.76, for a total value of $884,493.00.
• On Tuesday, July 29th, Adam Scott Levy sold 807 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $11,298.00.
• On Friday, July 11th, Adam Scott Levy sold 10,758 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $14.45, for a total value of $155,453.10.

Mineralys Therapeutics Stock Down 3.5%

MLYS traded down $0.49 during trading on Friday, hitting $13.66. The company's stock had a trading volume of 1,107,843 shares, compared to its average volume of 637,447. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $18.38. The stock's fifty day moving average price is $14.52 and its 200-day moving average price is $13.27. The firm has a market capitalization of $890.36 million, a P/E ratio of -3.66 and a beta of -0.29.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.23. Equities research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Mineralys Therapeutics

Several institutional investors have recently bought and sold shares of MLYS. SBI Securities Co. Ltd. grew its holdings in Mineralys Therapeutics by 297.5% during the first quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company's stock worth $25,000 after buying an additional 1,190 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Mineralys Therapeutics by 51.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company's stock worth $34,000 after buying an additional 850 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Mineralys Therapeutics during the fourth quarter worth $48,000. KLP Kapitalforvaltning AS bought a new stake in Mineralys Therapeutics during the second quarter worth $91,000. Finally, Quarry LP bought a new stake in Mineralys Therapeutics during the first quarter worth $111,000. Institutional investors own 84.46% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on MLYS shares. Wall Street Zen lowered Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and issued a $42.00 price objective on shares of Mineralys Therapeutics in a research note on Tuesday, June 17th. Jefferies Financial Group assumed coverage on Mineralys Therapeutics in a research note on Tuesday, June 10th. They issued a "hold" rating and a $15.00 price objective on the stock. Finally, Guggenheim set a $48.00 price objective on Mineralys Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $32.25.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.